AFP and neoplasm: Based on our early post-dose results, we conducted a prospective study to investigate the hypothesis that clinical changes (i.e., changes in tumor staining, AFP, and hepatic reserve) in the early post-dose period (i.e., 2 weeks post-dose) of sorafenib therapy are useful indicators of prognosis and therapeutic response.